Back to search
FDAFDA · Food and drugs·Recall number D-1540-2014

DOBUTamine Injection, USP, 250 mg per 20 mL, 20 mL Single-dose Fliptop Vial, Rx only, Manufactured for Hospira Inc., Lake Forest, IL 60045 USA. NDC 0409-2344-02

Published August 27, 2014 · Recall initiated: January 10, 2014

Summary

FDA records drug Class I recall D-1540-2014, published August 27, 2014 and initiated January 10, 2014. Recalling firm: Hospira Inc.; Status: Terminated; Reported quantity: 123,900 vials; Lot: Lot # 27-352-DK; Exp 03/15. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Discolored solution due to a chip in the glass at the neck of the vial, also glass particulate was found within the solution.

What to do

Voluntary: Firm initiated · Letter

Get an email if DOBUTAMINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DOBUTAMINE
Manufacturer
Hospira Inc.
Distributor
Nationwide and Puerto Rico.
Lot
Lot # 27-352-DK; Exp 03/15
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was DOBUTamine Injection, USP, 250 mg per 20 mL, 20 mL Single-dose Fliptop Vial, Rx only, Manufactured for Hospira Inc., Lake Forest, IL 60045 USA. NDC 0409-2344-02 recalled?

Yes. FDA published recall D-1540-2014 on August 27, 2014. Reported hazard: Presence of Particulate Matter: Discolored solution due to a chip in the glass at the neck of the vial, also glass particulate was found within the solution.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DOBUTAMINE.